195 related articles for article (PubMed ID: 19233181)
1. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.
Chan AT; Zauber AG; Hsu M; Breazna A; Hunter DJ; Rosenstein RB; Eagle CJ; Hawk ET; Bertagnolli MM
Gastroenterology; 2009 Jun; 136(7):2127-2136.e1. PubMed ID: 19233181
[TBL] [Abstract][Full Text] [Related]
2. CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.
Barry EL; Poole EM; Baron JA; Makar KW; Mott LA; Sandler RS; Ahnen DJ; Bresalier RS; McKeown-Eyssen GE; Ulrich CM
Cancer Causes Control; 2013 Jan; 24(1):47-54. PubMed ID: 23081681
[TBL] [Abstract][Full Text] [Related]
3. The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.
Chan AT; Hsu M; Zauber AG; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2012 Jan; 5(1):61-72. PubMed ID: 22030088
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib for the prevention of sporadic colorectal adenomas.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
[TBL] [Abstract][Full Text] [Related]
5. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.
Brenner SS; Herrlinger C; Dilger K; Mürdter TE; Hofmann U; Marx C; Klotz U
Clin Pharmacokinet; 2003; 42(3):283-92. PubMed ID: 12603175
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
Kraus S; Hummler S; Toriola AT; Poole EM; Scherer D; Kotzmann J; Makar KW; Kazanov D; Galazan L; Naumov I; Coghill AE; Duggan D; Gigic B; Arber N; Ulrich CM
Pharmacogenet Genomics; 2013 Aug; 23(8):428-437. PubMed ID: 23778325
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma.
Chan AT; Tranah GJ; Giovannucci EL; Hunter DJ; Fuchs CS
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):704-12. PubMed ID: 15290664
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
Kirchheiner J; Störmer E; Meisel C; Steinbach N; Roots I; Brockmöller J
Pharmacogenetics; 2003 Aug; 13(8):473-80. PubMed ID: 12893985
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.
Chan AT; Sima CS; Zauber AG; Ridker PM; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2011 Aug; 4(8):1172-80. PubMed ID: 21816845
[TBL] [Abstract][Full Text] [Related]
10. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Breazna A; Kim K; Tang J; Rosenstein RB; Umar A; Bagheri D; Collins NT; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Hawk ET;
Cancer Prev Res (Phila); 2009 Apr; 2(4):310-21. PubMed ID: 19336730
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
12. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
13. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
14. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.
Sandberg M; Yasar U; Strömberg P; Höög JO; Eliasson E
Br J Clin Pharmacol; 2002 Oct; 54(4):423-9. PubMed ID: 12392591
[TBL] [Abstract][Full Text] [Related]
15. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
[TBL] [Abstract][Full Text] [Related]
16. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.
Wang J; Carvajal-Carmona LG; Chu JH; Zauber AG; ; Kubo M; Matsuda K; Dunlop M; Houlston RS; Sieber O; Lipton L; Gibbs P; Martin NG; Montgomery GW; Young J; Baird PN; Ratain MJ; Nakamura Y; Weiss ST; Tomlinson I; Bertagnolli MM
Clin Cancer Res; 2013 Dec; 19(23):6430-7. PubMed ID: 24084763
[TBL] [Abstract][Full Text] [Related]
17. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
[TBL] [Abstract][Full Text] [Related]
18. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.
Bertagnolli MM; Hsu M; Hawk ET; Eagle CJ; Zauber AG;
Cancer Prev Res (Phila); 2010 May; 3(5):588-96. PubMed ID: 20403998
[TBL] [Abstract][Full Text] [Related]
19. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.
Prieto-Pérez R; Ochoa D; Cabaleiro T; Román M; Sánchez-Rojas SD; Talegón M; Abad-Santos F
J Clin Pharmacol; 2013 Dec; 53(12):1261-7. PubMed ID: 23996211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
